Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × sacituzumab govitecan × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 28 Triple Negative Breast Neoplasms 24 Carcinoma, Transitional Cell 9 Neoplasm Metastasis 8 Carcinoma, Non-Small-Cell Lung 8 Urinary Bladder Neoplasms 7 Lung Neoplasms 5 Endometrial Neoplasms 3 Brain Neoplasms 3 Small Cell Lung Carcinoma 2 Salivary Gland Neoplasms 2 Ovarian Neoplasms 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urothelial Bladder Carcinoma 1 Triple Negative Locally Advanced Non-resectable Breast Cancer 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasm, Residual 1 Mouth Neoplasms 1 Metastatic Urothelial Cancer 1

Interventions

Nivolumab 63 pembrolizumab 62 cabozantinib 43 Ipilimumab 33 Magnetic Resonance Spectroscopy 30 Specimen Handling 26 lenvatinib 21 Axitinib 20 belzutifan 16 Sunitinib 16 Radiosurgery 13 Biopsy 13 atezolizumab 10 Everolimus 10 CTLA-4 Antigen 10 pazopanib 9 avelumab 8 Radiotherapy 8 Bevacizumab 8 fludarabine 6 cemiplimab 6 aldesleukin 6 Standard of Care 6 Nephrectomy 6 Immunoglobulin G 6 Cyclophosphamide 6 toripalimab 5 spartalizumab 5 Paclitaxel 5 tivozanib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡